Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

First- and Second-Generation Antipsychotics for Children and Young Adults

Slide: 38 of 43

Summary of Adverse Effects of Second-Generation Antipsychotics

Current evidence indicates that there are differences between individual second-generation antipsychotics (SGAs) in the risk and severity of key adverse effects. However, in the absence of direct comparisons, subjective interpretations of relative risk and severity can be made using data from placebo comparisons.

In the current evidence base of direct comparisons of SGAs, statistically significant differences are noted in the rate or severity of dyslipidemia and in adverse changes in weight and body composition. Among the SGAs, olanzapine exhibits the most severe adverse effects on weight and blood lipids.

There is limited evidence of no statistically significant difference between SGAs in other direct comparisons of adverse effects (insulin and glucose control, extrapyramidal symptoms, and sedative effects).